

STATE OF SOUTH DAKOTA )  
:SS:  
COUNTY OF HUGHES )

IN CIRCUIT COURT  
SIXTH JUDICIAL CIRCUIT

STATE OF SOUTH DAKOTA *ex rel.*  
JASON R. RAVNSBORG, South  
Dakota Attorney General,

32CIV18-000065

Plaintiff,

v.

PURDUE PHARMA L.P.; PURDUE  
PHARMA, INC.; THE PURDUE  
FREDERICK COMPANY, INC.;  
JOHNSON & JOHNSON; JANSSEN  
PHARMACEUTICALS, INC.; ORTHO-  
MCNEIL-JANSSEN  
PHARMACEUTICALS, INC. n/k/a  
JANSSEN PHARMACEUTICALS, INC.;  
JANSSEN PHARMACEUTICA INC.  
n/k/a JANSSEN  
PHARMACEUTICALS, INC.; ENDO  
HEALTH SOLUTIONS INC.; ENDO  
PHARMACEUTICALS, INC.; PAR  
PHARMACEUTICAL, INC.; PAR  
PHARMACEUTICAL COMPANIES,  
INC. f/k/a PAR PHARMACEUTICAL  
HOLDINGS, INC.; ALLERGAN PLC  
f/k/a ACTAVIS PLC;  
ALLERGAN FINANCE LLC, f/k/a  
ACTAVIS INC., f/k/a WATSON  
PHARMACEUTICALS, INC.; WATSON  
LABORATORIES, INC., ACTAVIS LLC;  
ACTAVIS PHARMA, INC. f/k/a  
WATSON PHARMA, INC.;  
MALLINCKRODT LLC; SPECGX LLC;  
McKESSON CORPORATION;  
CARDINAL HEALTH, INC.; CARDINAL  
HEALTH 105, INC. d/b/a XIROMED,  
LLC; CARDINAL HEALTH 108, LLC  
f/k/a CARDINAL HEALTH 108, INC.;  
CARDINAL HEALTH 110, LLC d/b/a  
PARMED PHARMACEUTICALS;

**NOTICE OF ENTRY OF  
WALGREENS CONSENT  
JUDGMENT AND DISMISSAL  
WITH PREJUDICE**

CARDINAL HEALTH 200, LLC;  
CARDINAL HEALTH 414, LLC;  
CARDINAL HEALTH PHARMACY  
SERVICES, LLC;  
AMERISOURCEBERGEN DRUG  
CORPORATION; WALGREENS  
BOOTS ALLIANCE, INC.; WALGREEN  
CO.; WALMART INC. f/k/a WAL-  
MART STORES, INC; AND DOES 1  
THROUGH 100, INCLUSIVE,


Defendants.

GREETINGS FROM THE STATE OF SOUTH DAKOTA TO THE ABOVE-NAMED  
DEFENDANTS:

You will hereby take notice that on the 26th day of October 2023, the  
above Court made and entered its Walgreens Consent Judgment and Dismissal  
with Prejudice herein. Said Judgment was filed on October 26th, 2023, with  
the Hughes County Clerk of Courts. A true, correct and complete copy of the  
Walgreens Consent Judgment and Dismissal with Prejudice, except, due to the  
exhibits length, only the first page of the exhibits are attached, is hereunto  
annexed and herewith served upon you and made a part of this notice the  
same as if fully and completely set forth herein.

Dated this 7<sup>th</sup> day of November 2023, at Pierre, South Dakota.

STATE OF SOUTH DAKOTA



Charles D. McGuigan  
Deputy Attorney General  
1302 East Highway 14, Suite 1  
Pierre, SD 57501-8501  
Telephone: (605) 773-3215  
Email: Charles.McGuigan@state.sd.us

## CERTIFICATE OF SERVICE

The undersigned hereby certifies that on November\_\_\_\_, 2023, a true and correct copy of the Notice of Entry of Walgreens Consent Judgment was served electronically through Odyssey File & Serve or via email if the recipient(s) below are not registered with Odyssey system:

Sara Frankestein  
Matthew E. Naasz  
GUNDERSON, PALMER, NELSON, &  
ASHMORE LLP  
506Sixth Street  
P.O. Box 8045  
Rapid City, SD 57709-8045  
(605) 342-7078  
(605) 719-3471  
sfrankenstein@gpna.com  
mnaasz@gpna.com

Sheila L. Birnbaum (*admitted pro hac vice*)  
Mark S. Cheffo (*admitted pro hac vice*)  
Bert L. Wolff (*admitted pro hac vice*)  
Jonathan S. Tam (*admitted pro hac vice*)  
DECHERT LLP  
Three Bryant Park  
1095 Avenue of the Americas  
New York, NY 10036-6797  
(212) 698-3500  
Sheila.birnbaum@dechert.com  
Mark.cheffo@dechert.com  
Bert.wolff@dechert.com  
Jonathan.tam@dechert.com

*Attorney's for Purdue Pharma L.P., Purdue Pharma Inc., and The Purdue Frederick Company Inc.*

Jeffery D. Collins  
Thomas G. Fritz  
Barbara Lewis  
LYNN, JACKSON, SHULTZ & LEBRUN, PC  
jcollins@lynnjackson.com  
tfritz@lynnjackson.com  
blewis@lynnjackson.com  
Stephen D. Brody (*admitted pro hac vice*)  
O'MELVENY & MYERS LLP

1625 Eye Street, NW  
Washington, D.C. 20006  
(202) 383-5300  
sbrody@omm.com

Charles C. Lifland (*admitted pro hac vice*)  
Justine M. Daniels (*admitted pro hac vice*)  
O'MELVENY & MYERS LLP  
400 S. Hope St.  
Los Angeles, CA 90071  
(213) 430-6000  
clifland@omm.com  
jdaniels@omm.com

*Attorneys for Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc.*

Eric C. Schulte  
Anthony M. Hohn  
DAVENPORT, EVANS, HURWITZ & SMITH LLP  
eschulte@dehs.com  
ahohn@dehs.com

*Attorneys for Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.*

Daniel R. Fritz  
BALLARD SPAHR LLP  
fritzd@ballardspahr.com

*Attorney for Cardinal Health Inc.*

Shawn M. Nichols  
snichols@cadlaw.com

*Attorney for Mallinckrodt, LLC and SpecGX, LLC*

Robert Anderson  
MAY, ADAM, GERDES & THOMPSON LLP  
rba@mayadam.net

*Attorney for Walgreens Boots Alliance Inc. and Walgreen Co.*

Mark Haigh  
Edwin E. Evans

EVANS HAIGH & ARNDT LLP  
mhaigh@ehalawyers.com  
eevans@ehalawyers.com

*Attorneys for McKesson Corporation*

Scott Abdallah  
Erin Schoenbeck  
Ronald A. Parsons, Jr.  
scott@janklowabdallah.com  
erin@janklowabdallah.com  
ron@janklowabdallah.com

*Attorneys for Watson Laboratories, Inc. Actavis LLC & Actavis Pharma, Inc.  
f/k/a Watson Pharma, Inc.*

Daniel F. Duffy  
Emily Smoragiewicz  
Karla Macarthur Harris  
BANGS, MCCULLEN, BUTLER, FOYE & SIMMONS LLP  
dduffy@bangsmccullen.com  
emily@bangsmccullen.com  
kmharris@bangsmccullen.com

*Attorneys for AmerisourceBergen Drug Corporation*

Gary D. Jensen  
Jessica L. Larson  
Matthew J. McIntosh  
gjensen@blackhillslaw.com  
jlarson@blackhillslaw.com  
mmcintosh@blackhillslaw.com

*Attorneys for Walmart Inc.*

Jason R. Sutton  
BOYCE LAW FIRM, L.L.P.  
300 S. Main Avenue  
jrsutton@boycelaw.com

KIRKLAND & ELLIS LLP  
Jennifer G. Levy, P.C.  
jennifer.levy@kirkland.com

KIRKLAND & ELLIS LLP  
Donna Welch, P.C.  
donna.welch@kirkland.com

*Attorneys for Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson  
Pharmaceuticals, Inc. and Specially Appearing Allergan PLC f/k/a Actavis PLC*

Adam D. Teitcher  
Morgan, Lewis & Bockius LLP  
600 Anton Boulevard, Suite 1800  
Costa Mesa, CA 92626  
adam.teitcher@morganlewis.com

Brian M. Ercole  
Morgan, Lewis & Bockius LLP  
200 South Biscayne Boulevard, Suite 5300  
Miami, FL 33131-2339  
Brian.ercole@morganlewis.com

Steven A. Reed  
Morgan, Lewis & Bockius LLP  
1701 Market Street  
Philadelphia, PA 19103-2921  
Steven.reed@morganlewis.com

P. Benjamin Duke  
Covington & Burling LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018-1405  
pbduke@cov.com

Michael M. Maya  
Covington & Burling LLP  
One City Center  
850 Tenth Street, NW  
Washington, DC 20001-4956  
mmaya@cov.com

Dated this 7<sup>th</sup> day of November 2023.

STATE OF SOUTH DAKOTA



Charles D. McGuigan  
Deputy Attorney General  
1302 East Highway 14, Suite 1  
Pierre, SD 57501-8501  
Telephone: (605) 773-3215  
Email: Charles.McGuigan@state.sd.us

OF COUNSEL:

BARON & BUDD, P.C.

Russell Budd (*pro hac vice*)  
Christine Mansour (*pro hac vice*)  
3102 Oak Lawn Ave #1100  
Dallas, TX 75219  
(214) 521-3605  
rbudd@baronbudd.com  
cmansour@baronbudd.com

J. Burton LeBlanc, IV (*pro hac vice*)  
2600 Citiplace Dr.  
Baton Rouge, LA 70808  
(225) 927-5441  
bleblanc@baronbudd.com

Mark Pifko (*pro hac vice*)  
15910 Ventura Blvd., Suite 1600  
Encino, CA 91436  
(818) 839-2333  
mpifko@baronbudd.com

Jennifer Fountain Connolly (*pro hac vice*)  
600 New Hampshire Avenue NW  
10th Floor  
Washington, DC 20037  
(202) 333-4562  
jconnolly@baronbudd.com

STATE OF SOUTH DAKOTA )  
 ) :SS:  
COUNTY OF HUGHES )

IN CIRCUIT COURT  
SIXTH JUDICIAL CIRCUIT

STATE OF SOUTH DAKOTA *ex rel.*  
JASON R. RAVNSBORG, South  
Dakota Attorney General,

32CIV18-000065

Plaintiff,

v.

PURDUE PHARMA L.P.; PURDUE  
PHARMA, INC.; THE PURDUE  
FREDERICK COMPANY, INC.;  
JOHNSON & JOHNSON; JANSSEN  
PHARMACEUTICALS, INC.; ORTHO-  
MCNEIL-JANSSEN  
PHARMACEUTICALS, INC. n/k/a  
JANSSEN PHARMACEUTICALS, INC.;  
JANSSEN PHARMACEUTICA INC.  
n/k/a JANSSEN  
PHARMACEUTICALS, INC.; ENDO  
HEALTH SOLUTIONS INC.; ENDO  
PHARMACEUTICALS, INC.; PAR  
PHARMACEUTICAL, INC.; PAR  
PHARMACEUTICAL COMPANIES,  
INC. f/k/a PAR PHARMACEUTICAL  
HOLDINGS, INC.; ALLERGAN PLC  
f/k/a ACTAVIS PLC;  
ALLERGAN FINANCE LLC, f/k/a  
ACTAVIS INC., f/k/a WATSON  
PHARMACEUTICALS, INC.; WATSON  
LABORATORIES, INC., ACTAVIS LLC;  
ACTAVIS PHARMA, INC. f/k/a  
WATSON PHARMA, INC.;  
MALLINCKRODT LLC; SPECGX LLC;  
McKESSON CORPORATION;  
CARDINAL HEALTH, INC.; CARDINAL  
HEALTH 105, INC. d/b/a XIROMED,  
LLC; CARDINAL HEALTH 108, LLC  
f/k/a CARDINAL HEALTH 108, INC.;  
CARDINAL HEALTH 110, LLC d/b/a  
PARMED PHARMACEUTICALS;

**WALGREENS  
CONSENT JUDGMENT AND  
DISMISSAL WITH PREJUDICE**



CARDINAL HEALTH 200, LLC;  
CARDINAL HEALTH 414, LLC;  
CARDINAL HEALTH PHARMACY  
SERVICES, LLC;  
AMERISOURCEBERGEN DRUG  
CORPORATION; WALGREENS  
BOOTS ALLIANCE, INC.; WALGREEN  
CO.; WALMART INC. f/k/a WAL-  
MART STORES, INC; AND DOES 1  
THROUGH 100, INCLUSIVE,

Defendants.

#### **FINAL CONSENT JUDGMENT AND DISMISSAL WITH PREJUDICE**

The State of South Dakota (“*State*”) and Walgreen Co. (“*Walgreens*”) (together with the State, the “*Parties*,” and each a “*Party*”) have entered into a consensual resolution of the above-captioned litigation (the “*Action*”) pursuant to a settlement agreement dated as of December 9, 2022 (as subsequently updated) (the “*Agreement*”), a copy of which is attached hereto as Exhibit A. The Agreement shall become effective by its terms upon the entry of this Final Consent Judgment (the “*Consent Judgment*”) by the Court without trial or adjudication of any contested issue of fact or law, and without finding or admission of wrongdoing or liability of any kind.

#### **RECITALS:**

1. Each Party warrants and represents that it engaged in arm’s-length negotiations in good faith. In hereby executing the Agreement, the Parties intend to effect a good-faith settlement.
2. The State, acting through its Attorney General, has determined that the Agreement and entry of this Consent Judgment is in the public interest.

3. Walgreens denies the allegations against it and denies that it has any liability whatsoever to the State, its Subdivisions, and/or (a) any of the State's or its Subdivisions' departments, agencies, divisions, boards, commissions, districts, instrumentalities of any kind and attorneys, including its Attorney General, and any person in his or her official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, and other Special Districts in the State, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief on behalf of or generally applicable to the general public. Walgreens is entering into this Consent Judgment solely for the purpose of settlement, and nothing contained herein may be taken as or construed to be an admission or concession of any violation of law, rule, regulation, or ordinance, or of any other matter of fact or law, or of any fault, liability, or wrongdoing, all of which Walgreens denies.

4. The Parties recognize that the outcome of the Action is uncertain and a final resolution through the adversarial process likely will require protracted litigation.

5. The Parties agree to the entry of the injunctive relief terms attached as Exhibit P to the Agreement.

6. Therefore, without any admission of liability or wrongdoing by Walgreens or any other Released Entities (as defined in the Agreement), and without this Consent Judgment constituting evidence against or admission by anyone with respect to any issue of fact or law, the Parties now mutually consent to the entry of this Consent Judgment and agree to dismissal of the

claims with prejudice pursuant to the terms of the Agreement to avoid the delay, expense, inconvenience, and uncertainty of protracted litigation.

**NOW THEREFORE, IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:**

In consideration of the mutual promises, terms, and conditions set forth in the Agreement, the adequacy of which is hereby acknowledged by all Parties, it is agreed by and between Walgreens and the State, and adjudicated by the Court, as follows:

1. The foregoing Recitals are incorporated herein and constitute an express term of this Consent Judgment.

2. The Parties have entered into a full and final settlement of all Released Claims of Releasers (including but not limited to the State) against Walgreens and the Released Entities pursuant to the terms and conditions set forth in the Agreement. This Consent Judgment summarizes and gives effect to those terms. In the event of a conflict between the terms of the Agreement (including its exhibits) and language in this Consent Judgment, the terms of the Agreement shall govern. Nothing in this summary document shall have the effect of expanding, diminishing, explaining, or otherwise modifying any term of the Agreement.

3. The "Definitions" set forth in Section I of the Agreement are incorporated by reference into this Consent Judgment. The State is a "Settling State" within the meaning of the Agreement. Unless otherwise defined herein, capitalized terms in this Consent Judgment shall have the same meaning given to them in the Agreement.

4. The Parties agree that the Court has jurisdiction over the subject matter of the Action and over the Parties with respect to the Action and this Consent Judgment. This Consent Judgment shall not constitute and shall not be construed or used as a waiver of any jurisdictional defense Walgreens or any other Released Entity may raise in any other proceeding.

5. The Court finds that the Agreement was entered into in good faith and is in the public interest, and that entry of this Consent Judgment is in the public interest. By this Consent Judgment, the Agreement is hereby approved by the Court.

6. The State's Claims against Walgreens are hereby DISMISSED WITH PREJUDICE, subject to a retention of jurisdiction by the Court as provided herein and in the Agreement.

7. The Court shall have authority to resolve disputes identified in Section VI.F.1 of the Agreement, governed by the rules and procedures of the Court.

8. By this Consent Judgment, the South Dakota Opioid Memorandum of Agreement, a copy of which is attached hereto as Exhibit [C] and as incorporated into the Agreement pursuant to Exhibit O of the Agreement, is hereby approved by the Court as the means by which relevant funds paid pursuant to the Agreement will be divided within the State, provided that any Subdivision receiving such funds executes a Subdivision Participation Agreement accepting the terms of the Agreement, including the releases provided therein. Also see SDCL 34-20B-1.

9. The Parties have satisfied the Condition to Effectiveness of Agreement set forth in Section VIII of the Agreement and the Release set forth in Sections X.A and F of the Agreement, as follows:

- a. The Attorney General of the State exercised the fullest extent of his or her powers to release Walgreens and all other Released Entities from all Released Claims pursuant to the release attached hereto as Exhibit B (the "AG Release").
- b. Walgreens has determined to proceed with the Agreement.
- c. The Subdivision Participation Agreement for each Participating Subdivision in the State that has joined to date has been made available to Walgreens. As stated in the Subdivision Participation Agreement, and for the avoidance of doubt, nothing in the Subdivision Participation Agreement executed by the Participating Subdivisions is intended to modify in any way the terms of the Agreement to which the Participating Subdivisions agree. As stated in the Subdivision Participation Agreement, to the extent the terms of the executed version of the

Subdivision Participation Agreement differ from the terms of the Agreement in any respect, the terms of the Agreement control.

- d. Pursuant to Section VIII.B of the Agreement and Paragraph 2 of the Subdivision Participation Agreement, each Litigating Subdivision in the State that has become a Participating Subdivision is dismissing with prejudice any Released Claims that it has filed against Walgreens or any of the Released Entities.

10. Release. The Parties acknowledge that the release provisions in Section X of the Agreement and the AG Release, which are incorporated by reference herein, are an integral part of this Consent Judgment. Pursuant to the Agreement and the AG Release and without limitation and to the maximum extent of the power of the State's Attorney General, Walgreens and the other Released Entities are, as of the Effective Date, hereby released from any and all Released Claims of (a) the State and its Participating Subdivisions and any of their departments, agencies, divisions, boards, commissions, Subdivisions, districts, instrumentalities of any kind and attorneys, including the State's Attorney General, and any person in his or her official capacity whether elected or appointed to serve any of the foregoing, and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, and other Special Districts in the State, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief on behalf of or generally applicable to the general public with respect to the State or any Subdivision in the State, whether or not any of them participate in the Agreement. Pursuant to the Agreement and the AG Release and to the maximum extent of the State's power, Walgreens and the other Released Entities are, as of the Effective Date, hereby released from any and all Released Claims of (1) the State, (2) all past and present executive departments, state agencies, divisions, boards, commissions and instrumentalities with the regulatory authority to enforce state and federal controlled substances acts, and (3) any of the State's past and present executive departments,

agencies, divisions, boards, commissions and instrumentalities that have the authority to bring Claims related to Alleged Harms seeking money (including abatement and/or remediation) or revocation or suspension of a pharmaceutical distribution or dispensing license. For the purposes of clause (3) above, executive departments, agencies, divisions, boards, commissions, and instrumentalities are those that are under the executive authority or direct control of the State's Governor. Further, the provisions set forth in Section X of the Agreement are incorporated by reference into this Consent Judgment as if fully set forth herein. The Parties acknowledge, and the Court finds, that those provisions are an integral part of the Agreement and this Consent Judgment, and shall govern the rights and obligations of all participants in the settlement, including without limitation the State, Walgreens and the Released Entities.

11. Release of Unknown Claims. The State (for itself and its Releasers) expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:

**General Release; extent.** A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The State may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but the State (for itself and its Releasers) expressly waived and fully, finally, and forever settled, released and discharged, through the Agreement and AG Release, any and all Released Claims that may exist as of the Effective Date but which the State does not know or suspect to exist, whether through ignorance, oversight, error,

negligence or through no fault whatsoever, and which, if known, would have materially affected the State's decision to enter into the Agreement.

12. The Court finds that the releases are given in good faith and are effective as to all Releasers and Released Entities.

13. Costs and Fees. The Parties will bear their own costs and attorneys' fees except as otherwise provided in the Agreement.

14. No Admission of Liability. Walgreens is consenting to this Consent Judgment solely for the purpose of effectuating the Agreement, and nothing contained herein may be taken as or construed to be an admission or concession of any violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability or wrongdoing, all of which Walgreens expressly denies. Neither Walgreens nor any other Released Entity admits that it caused or contributed to any public nuisance, and neither Walgreens nor any other Released Entity admits any wrongdoing that was or could have been alleged by the State, its Participating Subdivisions, or any other person or entity. No part of this Consent Judgment shall constitute evidence of any liability, fault, or wrongdoing by Walgreens or any other Released Entity. The Parties acknowledge that payments made under the Agreement are not a fine, penalty, or payment in lieu thereof and are properly characterized as described in Section V.F of the Agreement.

15. No Waiver. This Consent Judgment is entered based on the Agreement without trial or adjudication of any contested issue of fact or law or finding of liability of any kind. This Consent Judgment shall not be construed or used as a waiver of Walgreens' right, or any other Released Entity's right, to defend itself from, or make any arguments in, any other regulatory, governmental, private individual, or class claims or suits relating to the subject matter or terms of

this Consent Judgment. Notwithstanding the foregoing, the State may enforce the terms of this Consent Judgment as expressly provided in the Agreement.

16. No Private Right of Action. This Consent Judgment is not for use by any third party for any purpose, including submission to any court for any purpose, except Participating Subdivisions for the limited purposes set forth in Section VI.A of the Agreement. Except as expressly provided in the Agreement, no portion of the Agreement or this Consent Judgment shall provide any rights to, or be enforceable by, any person or entity that is not a Settling State or Released Entity. The State shall allow Participating Subdivisions in the State to notify it of any perceived violations of the Agreement or this Consent Judgment. No Settling State, including the State, may assign or otherwise convey any right to enforce any provision of the Agreement.

17. Admissibility. This Consent Judgment shall not be admissible in any other case against Walgreens or any other Released Entity. This Consent Judgment shall not be binding on Walgreens or any other Released Entity in any respect other than in connection with the enforcement of this Consent Judgment or the Agreement in the State. For the avoidance of doubt, nothing herein shall prohibit Walgreens or any other Released Entity from entering this Consent Judgment or the Agreement into evidence in any litigation or arbitration concerning (1) Walgreens' right to coverage under an insurance contract or (2) the enforcement of the releases provided for by the Agreement and this Consent Judgment.

18. Preservation of Privilege. Nothing contained in the Agreement or this Consent Judgment, and no act required to be performed pursuant to the Agreement or this Consent Judgment, is intended to constitute, cause, or effect any waiver (in whole or in part) of any attorney-client privilege, work product protection, patient-safety work product protection, or



common interest/joint defense privilege, and each Party agrees that it shall not make or cause to be made in any forum any assertion to the contrary.

19. Mutual Interpretation. The Parties agree and stipulate that the Agreement was negotiated on an arm's-length basis between parties of equal bargaining power and was drafted jointly by counsel for each Party. Accordingly, the Agreement is incorporated herein by reference and shall be mutually interpreted and not construed in favor of or against any Party.

20. Retention of Jurisdiction. The Court shall retain jurisdiction over the Parties for the limited purpose of the resolution of disputes identified in Section VI.F.1 of the Agreement. The Court shall have jurisdiction over Participating Subdivisions in the State for the limited purposes identified in the Agreement.

21. Successors and Assigns. This Consent Judgment is binding on Walgreens' successors and assigns.

22. Modification. This Consent Judgment shall not be modified (by the Court, by any other court, or by any other means) without the consent of the State and Walgreens and without the approval of the Court. Modification of the Agreement shall be governed by Section XIII.W of the Agreement.

So ORDERED this 26<sup>th</sup> day of October, 2023.

BY THE COURT:



The Honorable David R. Gienapp,  
Circuit Court Judge, Retired

Attest:  
Deuter-Cross, Tara Jo  
Clerk/Deputy



APPROVED, AGREED TO AND PRESENTED BY:  
FOR THE STATE OF SOUTH DAKOTA

/s/ Charles D. McGuigan

Charles D. McGuigan  
Deputy Attorney General  
1302 East Highway 14, Suite 1  
Pierre, SD 57501-8501  
Telephone: (605) 773-3215  
Email: Charles.McGuigan@state.sd.us

Attorney for Walgreens



Robert B. Anderson  
Attorney at Law  
PO Box 160  
Pierre, SD 57501  
rba@mayadam.net

As of October 13, 2023

**WALGREENS SETTLEMENT**  
**AGREEMENT**

**EXHIBIT**  
**A**

**Attorney General's Release of Opioid-Related Claims Pursuant to the  
Walgreens Settlement Agreement**

WHEREAS the Walgreens Settlement Agreement dated December 9, 2022 (the "Agreement") provides in Section X.A that, as of the Effective Date of the Agreement, Walgreens and the Released Entities will be released and forever discharged from all of the Releasers' Released Claims;<sup>1</sup> and

WHEREAS the Agreement provides in Section I.NNN that Releasers (as defined in the Agreement) who are releasing claims under Section X.A include without limitation and to the maximum extent of the power of each Settling State's Attorney General to release Claims (a) the Settling State's and Participating Subdivision's departments, agencies, divisions, boards, commissions, Subdivisions, districts, instrumentalities of any kind and attorneys, including its Attorney General, and any person in his or her official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, and other Special Districts in a Settling State, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief on behalf of or generally applicable to the general public with respect to a Settling State or Subdivision in a Settling State, whether or not any of them participate in this Agreement; and

WHEREAS the Agreement provides in Section X.F that each Settling State's Attorney General expressly represents and warrants that he or she has, or has obtained, the authority to settle and release, to the maximum extent of the State's power, all Released Claims of (1) his or her respective Settling State, (2) all past and present executive departments, state agencies, divisions, boards, commissions and instrumentalities with the regulatory authority to enforce state and federal controlled substances acts, and (3) any of his or her respective Settling State's past and present executive departments, agencies, divisions, boards, commissions and instrumentalities that have the authority to bring Claims related to Covered Conduct seeking money (including abatement and/or remediation) or revocation or suspension of a pharmaceutical distribution or dispensing license. For the purposes of clause (3) above, executive departments, agencies, divisions, boards, commissions, and instrumentalities are those that are under the executive authority or direct control of the State's Governor;[ and

*WHEREAS the Agreement provides in Section X.F that a release from a Settling State's Governor is sufficient to demonstrate that the appropriate releases have been obtained for the purposes of clause (3) of Section X.F, and the Governor of the [Commonwealth/State/Territory] of [\*] has provided a release;]*

THEREFORE, pursuant to the foregoing provisions of the Agreement and without limitation and to the maximum extent of the power of the Attorney General, the Released Entities are, as of the Effective Date, hereby released from any and all Released Claims of (a) the

---

<sup>1</sup> Capitalized terms used herein and defined in the Agreement have the meanings given to them in the Agreement.

# South Dakota Opioid Settlement

## Memorandum of Agreement

**Whereas**, the people of the State of South Dakota and its communities have been harmed by serious and substantial wrongdoing committed by certain entities within the Pharmaceutical Supply Chain;

**Whereas**, the State of South Dakota, through its Attorney General, and certain Participating Local Governments have separately engaged in investigation, litigation, and settlement discussions seeking to hold Pharmaceutical Supply Chain Participants accountable for the damage they have caused in South Dakota;

**Whereas**, other Participating Local Governments, while not engaged in separate litigation, have supported the State's efforts in the legal fight against the opioid crisis;

**Whereas**, the State and all Participating Local Governments share a common desire to abate and alleviate the impacts of the Pharmaceutical Supply Chain Participants' misconduct throughout the State of South Dakota;

**Whereas**, jointly approaching Settlements with Pharmaceutical Supply Chain Participants benefits all Parties by improving the likelihood of successful Settlement and maximizing the recovery from any such Settlement;

**Whereas**, specifically, the State and Participating Local Governments understand that Settlements with major Pharmaceutical Supply Chain Participants have taken the form of a national resolution (National Settlement Agreement);

**Whereas**, the State and Participating Local Governments intend this agreement to facilitate their compliance with the terms of the National Settlement Agreement;

**Whereas**, the State and Participating Local Governments understand that the National Settlement Agreement provides a default allocation between each state and its political subdivisions unless they enter into a state-specific agreement regarding the distribution and use of payments (State-Subdivision Agreement);

**Whereas**, specifically, the State and Participating Local Governments intend this agreement to serve as a State-Subdivision Agreement under the National Settlement Agreement involving Johnson & Johnson, AmerisourceBergen, Cardinal Health, and McKesson, and Bankruptcy Resolutions concerning Purdue Pharma, L.P. and Mallinckrodt plc entered into by the State and the Participating Local Governments;

**Now, therefore**, in consideration of the foregoing, the State and its Participating Local Governments, enter into this "South Dakota Opioid Settlement Memorandum of Agreement" (MOA) relating to the allocation and use of the proceeds of any Settlement as described in this MOA;